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Introduction
Depression impairs cognitive processes, including memory, atten-
tion, executive function and motor function (Austin et al., 2001).
Although serotonin (5-hydroxytryptamine; 5-HT) neurotransmis-
sion plays an important role in the pathophysiology of depression
(Maes and Meltzer, 1995), the relationship of 5-HT, depressed
mood and cognitive processes remains poorly understood. In the
acute tryptophan depletion (ATD) paradigm, 5-HT function is tem-
porarily lowered by restricting the availability of its precursor 
L-Tryptophan (Trp) (Young et al., 1985). It has frequently been
demonstrated that ATD temporarily induces a return of depressive
symptoms in a subset of selective serotonin reuptake inhibitor
(SSRI) treated remitted depressed patients (Delgado et al., 1990,
1999; Van der Does, 2001a; Booij et al., 2002, 2003). However, the
effects of ATD on cognitive processes in these patients have not
been studied.
In healthy samples, ATD had a selective negative effect on
memory consolidation for verbal and non-verbal material (Park et
al., 1994; Riedel et al., 1999; Schmitt et al., 2000; Sobczak et al.,
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It has frequently been demonstrated that acute tryptophan depletion
(ATD) induces a transient depressed mood in some patients who are in
remission from depression. However, the effects of ATD on cognitive
processes in remitted depressed patients have not been investigated.
The aim of the present study was to investigate the effects of different
extents of depletion on mood and cognitive tasks involving neutral and
emotional stimuli. Twenty patients in remission or in partial remission
from depression received ATD in a double-blind, crossover design. Mood
was assessed at both sessions before, at +6.5 h and +24 h after 
depletion. Cognitive assessment in both sessions started at +4.75 h, and
also before and after the whole procedure. The ATD mixtures induced the
expected reductions of plasma tryptophan levels. High-dose ATD induced
a depressive response in a subsample of patients and impaired the 
processing of positive information independent of mood change.
Attention for neutral stimuli (Stroop interference) improved in a dose-
dependent manner. ATD may affect mood and cognition via different
pathways: one implicated in mood regulation and the processing of 
emotional information, and one for the processing of neutral 
information. The first pathway may be more important for discriminating
vulnerability to impaired serotonin function. The comparison of the
effects of high-dose and low-dose ATD is useful for those studies aiming
to investigate the relationships among 5-HT, mood and cognition.
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2002; Harrison et al., 2004), and a positive effect on focused attention
as indicated by reduced Stroop interference or by improved dicho-
tic listening performance (Park et al., 1994; Schmitt et al., 2000).
Of particular interest are ATD studies investigating the effects
on emotional material because a mood-congruent bias has often
been demonstrated in depression. For example, depressed patients
are more likely to learn and retrieve negative than positive infor-
mation (Burt et al.1995). Research with the Emotional Stroop test
has shown that depression-related words cause more interference
than neutral or positive words (Gotlib, 1984; Segal et al., 1995).
Consistent with this, ATD in healthy volunteers impaired the pro-
cessing of positive information (Murphy et al., 2002) and
decreased the recognition of fearful faces (Harmer et al., 2003b)
but left mood unaffected. The results of these studies suggest that
cognitive tests may be more sensitive measures of ATD-induced
depression than mood scales.
However, the absence of depressive response in healthy 
samples limits the use of these samples in investigating the associ-
ations among 5-HT, depressive symptoms and cognitive function.
If cognitive changes are more sensitive markers for changes in 
5-HT function than symptom, changes in cognitive function fol-
lowing ATD may occur in patients without a depressive response.
Second, cognitive changes may already occur after moderate
depletion, with no effect on symptoms.
It has been suggested that failures to replicate the mood effects
of ATD may have been due to insufficient depletion (Spillmann et
al., 2001; Van der Does, 2001b). Therefore, although all previous
studies have used a placebo-controlled design, it has been recom-
mended to compare the effects of two different dosages of ATD
(100 g versus 25 g amino acids), aimed at reducing plasma Trp 
levels by 80–90% and 40–50%, respectively (Van der Does, 2001a).
The aim of the present study was to investigate the effects of
moderate and strong reductions of Trp levels on mood and on cog-
nitive tasks involving neutral and affective stimuli, in remitted
depressed patients. The tested hypotheses were: (i) strong reduc-
tions of Trp levels, and not moderate reductions, will lead to a 
transient return of depressive symptoms and (ii) both moderate and
strong reductions of Trp will lead to cognitive changes in patients
with and without an ATD induced depressive response.
Materials and methods 
Participants
Eligible patients were selected outpatients of a mood disorders
clinic. Inclusion criteria were: age between 18 and 65 years; ongo-
ing treatment with an SSRI or a serotonin noradrenaline reuptake
inhibitor for at least 4 weeks, meeting DSM-IV criteria for depres-
sion in remission or partial remission, Hamilton Depression rating
Scale (HRSD, 17-items) (Hamilton, 1960) lower than 15 (Frank 
et al., 1991). Exclusion criteria were: substance abuse within last 
3 months, psychosis (lifetime), major physical illness, lactation,
pregnancy. Diagnoses, demographic and clinical background 
variables were verified with the Structured Clinical Interview for
DSM-IV (SCID-I) (First et al., 1995).
Amino acids
At each depletion session, patients received in randomized order
either a high-dose (100 g) or a low-dose (25 g) ATD mixture. The
composition of the 100-g mixture (aimed at reducing Trp levels by
90%) was similar to that reported by Delgado et al., 1990). The 
25-g mixture consisted of the same amino acids (AAs) but at one
quarter of the amount (Krahn et al., 1996). All AAs were mixed
with cold water (4 °C) to a final volume of 300 ml. Liquid choco-
late syrup was added and the mixture was served chilled to limit
the unpleasant taste of some AAs. Patients were kept on a 24-h
low-Trp diet (160 mg/day) before both sessions. The meals had an
energy value of 2300 kCal and were prepared by dieticians. During
the ATD sessions, water (de)caffeinated coffee, (herbal) tea, orange
juice and protein-poor (< 0.05 g) cookies were allowed in standard
amounts. Caffeinated coffee or tea was not allowed to be consumed
for approximately 1 h before the cognitive tasks. The experimenter
took care that the amount of caffeine consumed was not larger than
usual. Patients had a low-Trp lunch 3 h after drinking the mixture
(Riedel et al., 1999; Schmitt et al., 2000; Sobczak et al., 2002)
Instruments
Mood Symptoms were assessed with the 10-item Montgomery–
Asberg Depression Rating Scale (MADRS) (Montgomery and
Asberg, 1979). Sleep items were omitted. The 17-item HRSD was
also administered. Because the results were very similar, only the
MADRS will be reported.
Cognition The cognitive tests took approximately 60 min. Parallel
versions were used, except for the Stroop tasks and the Left/Right
task.
Stroop Word Colour test
The Stroop test measures focused attention and response inhibi-
tion. Names of colors (red, yellow, blue and green) printed in black
were presented one by one for a maximum of 1500 ms on a com-
puter screen. Participants were instructed to read these words as
fast as possible (Condition I). Next, colored patches were presented
(Condition II). Finally, the names of colors printed in an incongruent
colour were presented and participants were instructed to name the
colour of the ink (Condition III). Median reaction times (RTs) and
errors were recorded. Interference was defined as the extra time
needed for condition III relative to the average of conditions I and II.
Emotional Stroop test
An Emotional Stroop test was used to assess attentional bias for
emotional material. The stimuli were positive, neutral or depression-
related words. Words printed in colour were presented consecu-
tively on a computer screen. Participants were asked to name the
colors as quickly as possible. The order of the word categories was
randomized over the patients but fixed for each patient during all
sessions. The order of the words within each category was random-
ized in all sessions.
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Left/Right Choice RT
This task was used to assess motor speed and response inhibition
as a function of task difficulty. The word ‘left’ or ‘right’ was pre-
sented in randomized order either at the left or the right side of the
screen. Participants were instructed to respond to the meaning of
the word but to ignore its location, as fast as possible. The task con-
sisted of two consecutive subtasks in which the stimulus interval
differed (1000 ms fixed versus 500–1500 ms variable). Correct
responses and RTs were registered.
Tower of London (TOL)
The TOL (Owen et al., 1995) is a planning task consisting of three
colored balls (red, yellow and blue) placed on three sticks in vari-
ous arrangements. Two arrangements were presented on the upper
and lower half of the screen. The patient was instructed to indicate
the minimal number of moves necessary to change the first
arrangement into the second (two to six moves). Correct responses
and RTs were registered.
Letter Fluency
This test measures strategy-driven retrieval from semantic memory
within a fixed time span. Participants were instructed to produce as
many correct four-letter words with the same initial letter as pos-
sible within 1 min. Starting letters were H, M, R and L. The numbers
of correct, nonsense and double-reported words were registered.
Abstract Patterns Recognition task (APRT)
The APRT (Rubinsztein et al., 2001) measures (speed of) retrieval
of non-verbal abstract information from short- and long-term
memory. Sixteen abstract patterns were presented consecutively
for 3000 ms, with 500 ms intervals. Participants were instructed to
memorize the patterns. After three presentations of the complete
series, two patterns were presented simultaneously; one that had
been learned and a new pattern. Participants had to indicate as fast
as possible which one had been previously presented. The recogni-
tion procedure was repeated after 35 min, during which verbal
tasks were administered.
Blood plasma
Venous blood was obtained (10 ml) using ethylenediaminete-
traacetic acid tubes to determine total plasma Trp and the other
large neutral amino acids (LNAA) phenylalanine, tyrosine, isoleuc-
ine, leucine and valine. Immediately after sampling, the blood was
centrifuged for 20 min at 2650 g (maximum) and the plasma was
stored at –65 °C. Quantitative amino acid analysis was performed
by high-performance liquid chromatography (HPLC) as described
previously (Fekkes et al., 1995). The concentrations 5-hydroxy-
indoleacetic acid (5-HIAA) and homovanillic acid (HVA) were
measured in plasma by HPLC employing electrochemical detec-
tion (detection limit in plasma, 1 nM). Quantification was performed
by measuring peak heights, and absolute concentrations were 
calculated using a combined external and internal standard (apply-
ing α-methyl 5-HT) method (Fekkes et al., 1997).
Procedure
After providing their written informed consent, participants were
invited to a screening interview that included the SCID-I, HRSD,
MADRS and an interview with a dietician. The cognitive tasks
were also administered. The time between the intake and the first
ATD session was approximately 1 week. During day 1 of each ses-
sion, patients consumed the prepacked low-Trp meal. Patients
came to the laboratory at 08.00 h or 09.00 h of day 2, after an
overnight fast. Mood ratings and a blood sample were obtained 
(–1 h), followed by the ATD drink (0 h). For the next 4.5 h, patients
remained in a private research room. Neutral videos and magazines
were available. They completed the cognitive tasks at +4.75 h. A
blood sample was taken at +6 h and mood was assessed at +6.5 h.
Before participants went home, they received a sandwich or a Trp-
enriched snack and were instructed to resume their regular meals.
Mood ratings and a blood sample were taken the next morning.
This procedure was repeated at least 4 days later; those who had
received high-dose ATD received low-dose ATD and vice versa.
The day after the second session, participants also completed the
cognitive test battery (after the mood assessment). All patients
were tested individually and were paid €115 for their participation.
Design
The study was conducted according to a randomized, double-blind,
crossover design with two sessions, separated by at least 4 days.
The hospital pharmacist took care of the randomization. To 
compare the effects of both low- and high-dose ATD with baseline
levels, cognitive performance after ATD was compared with the
mean of the first and the fourth administration of the neuropsycho-
logical tests.
Statistical analysis
Before analysis, all variables were examined for accuracy of data-
entry, missing values and fit between their distributions and the
assumptions of the statistical analyses. Clinical and demographic
variables were investigated by means of chi-square tests and 
univariate General Linear Models (GLM). Differences in mood
and cognitive performance between patients and controls were
analysed by multivariate GLM.
The effects of the different doses of ATD on the outcome vari-
ables were analysed by GLM for repeated measures. For the
MADRS, intervention (low-dose versus high-dose) and time (–1 h,
+6.5 h and +24 h) were the within subjects factors. Intervention
(baseline versus low-dose versus high-dose ATD) was used as
within-subject factor for the cognitive measures. ‘Baseline inter-
vention’ measures were defined as the average score obtained 
during the intake and post-intervention sessions. Contrast tests
were used to investigate differences between specific interventions.
p-values for contrast tests were corrected for multiple comparisons
by dividing the p-value of 0.05 by the number of intervention 
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comparisons (baseline versus low-dose; baseline versus high-dose;
low-dose versus high-dose), implicating that differences between
interventions were tested at the 0.05/3 = 0.02 level of significance.
To further investigate the relationship between depressive symp-
toms, cognitive function and 5-HT, post-hoc analyses were con-
ducted by adding ATD depressive response (‘responder’ versus
‘non-responder’) as a between subjects variable, based on a clear
division in magnitude of symptom change between the groups 
(see below). Second, the influences of minor mood changes were
investigated by separate analyses entering delta MADRS scores 
[t +6.5 h – t (–1 h) following high-dose ATD] as a covariate.
There was no need to correct the p-value for the effects of ATD
on depressive symptoms because these comparisons were planned,
based on previous ATD studies in remitted depressed patients
(Booij et al., 2002, 2003).
Results
Twenty-three participants entered the study (13 males, 10 females).
Two patients (both males) dropped out after the first session; the
first case due to a severe headache on the depletion day (after low-
dose ATD) and the second case because of health problems after
the first session (high-dose ATD) unlikely to be caused by ATD.
These patients were not included in the analyses. The ATD mix-
tures were well tolerated; one female patient vomited approximately
10 min after ingestion of high-dose ATD, but she was able to com-
plete both sessions. Because the reduction of plasma Trp levels in
the high-dose condition was only marginally higher than in the
low-dose condition in this participant (64% versus 55%) and much
lower than the average reduction in the high-dose condition (see
below), this patient was excluded from the analyses.
The clinical and demographic characteristics of the remaining,
20 patients are presented in Table 1. Two patients had very recently
tapered off antidepressant medication. These patients were retained
because unmedicated remitted depressed patients are also likely to
respond to ATD (Smith et al., 1997; Booij et al., 2002).
Data screening
RTs of the TOL and the APRT were log10-transformed because of
a non-normal distribution. Using Mahalonobis distances and stan-
dardized residuals criterion, one statistical outlier was detected on
the MADRS (D2 = 16.2; z = 3.2). This patient responded in the
low-dose ATD condition and not after high-dose ATD. Another
patient had an extreme increase in neutral Stroop interference 
levels after high-dose ATD (D2 = 14.7; z = 3.05), and was a statis-
tical outlier. One patient experienced a strong emotional reaction
during the emotional Stroop task and interrupted the task. Another
patient missed all 3- and 4-step problems of the TOL at intake and
after the low-dose ATD session. Blood samples were missing for
one patient at the post intervention day after both sessions.
Analyses were conducted with and without statistical outliers.
Cases with missing data were omitted separately by analysis.
Biochemical effects
Both ATD mixtures significantly reduced total Trp and the Trp/
LNAA ratio. Total Trp was significantly more reduced after a high
than after low-dose ATD (mean ± SE change: –86.3 ± 1.2% versus
–46.8 ± 3.2%). A similar pattern was observed for Trp/LNAA ratio
(–93.3 ± 0.9% versus –42.2 ± 3.8%). The variance of reductions
was small; for each patient, the reduction was approximately twice
as large after a high-dose than after a low-dose.
Post-hoc analyses were conducted to investigate the effects of
ATD on tyrosine levels. Unexpectedly, tyrosine levels and tyrosine/
LNAA ratio increased significantly after a high-dose ATD (mean ±
SE change: +214.0 ± 25.3% and +56.4 ± 14.5%), but not after a
low-dose ATD (–2.0 ± 3.8% and +11.2 ± 3.6%). To further inves-
tigate the influence on dopamine (DA) and 5-HT function, HVA
and 5-HIAA levels were measured post-hoc in the first 10 patients.
At t(+6.5 h), high-dose ATD significantly decreased 5-HIAA levels
compared to t(–1 h) (–50.3%) [F(1,9) = 108.85, p < 0.001]. There
was no significant change of HVA levels (–23.6%) [F(1,9) = 0.76,
not significant]. After omitting one patient who had extremely high
HVA levels before depletion, the change in HVA levels was +3.3%.
Symptoms
The increase of MADRS scores at t(+6.5 h) was significantly higher
after high-dose ATD than after low-dose ATD, as shown by a 
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Age ± SD 48.7 ± 7.9
Education level
High n = 9
Medium n = 7
Low n = 3
Type of medication
SSRI n = 13 (two SSRI treatment
free for 1 month)
SNRI n = 7 (75–225 mg)
Diagnosis
Subtype of last depressive episode:
Not melancholic, atypic or catonic n = 3
Melancholic n = 11
Atypic n = 6
Seasonal pattern n = 2
Mean ± SD past episodes 4.8 ± 4.4 (range 1–16)
Single/recurrent 4/16
Partial remission n = 13
Full remission n = 7
Duration of remission(months) ± SD 5.9 ± 5.6 (range 1–24)
SSRI, Selective serotonin reuptake inhibitor; SNRI, serotonin noradrena-
line reuptake inhibitor.
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Table 2 Effects of acute tryptophan depletion (ATD) on the biochemical outcome measures and mood (mean ± SE)
Low-dose ATD High-dose ATD
Pre Post + 24h Pre Post + 24h
Total TRP 38.4 ± 1.5 20.4 ± 1.6 38.0 ± 1.6 39.4 ± 1.3 5.3 ± 0.5 35.6 ± 1.8
TRP/LNAA 8.7 ± 0.3 4.9 ± 0.3 7.2 ± 0.3 9.1 ± 0.3 0.6 ± 0.1 6.3 ± 0.3
5-HIAA 28.2 ± 1.9 14.1 ± 1.1
Tyrosine 57.3 ± 2.9 56.2 ± 3.5 62.2 ± 4.9 58.0 ± 3.5 173.4 ± 11.5 67.0 ± 6.3
Tyrosine/LNAA 13.4 ± 0.5 14.9 ± 0.8 11.9 ± 0.6 13.6 ± 0.6 20.6 ± 1.4 11.9 ± 0.5
HVA 85.2 ± 25.9 65.1 ± 10.7
MADRS 3.7 ± 0.9 3.7 ± 0.9 3.6 ± 0.9 4.6 ± 0.9 7.9 ± 1.8 3.4 ± 1.0
TRP, L-Tryptophan; LNAA, large neutral amino acids; 5-HIAA, 5-hydroxyindoleacetic acid; HVA, homovanillic acid; MADRS, Montgomery–Asberg
Depression Rating Scale.
Table 3 Mean ± SE of the cognitive tasks, broken down by intervention
Task Baselinea Low-dose ATD High-dose ATD Intervention effect
SCWT
Condition I (ms) 498.5 ± 12.4 519.2 ± 10.6b 534.8 ± 11.6b F(2,38) = 5.52, p = 0.01
Condition II (ms) 558.5 ± 16.9 550.6 ± 13.3 577.9 ± 16.4 F(2,38) = 2.13, p = 0.13
Condition III (ms) 789.2 ± 25.0 759.8 ± 22.0 762.7 ± 24.1 F(2,38) = 1.80, p = 0.18
Interference (%) 48.3 ± 3.3 42.4 ± 3.4c 34.7 ± 2.9b F(2,36) = 9.85, p < 0.001
Emotional Stroop
Positive words (ms) 707.1 ± 18.0 709.8 ± 19.9 717.2 ± 20.0 F(2,36) = 0.22, p = 0.80
Negative words (ms) 737.3 ± 21.2 724.0 ± 23.9 708.1 ± 21.6 F(2,36) = 1.47, p = 0.24
Neutral words (ms) 711.4 ± 16.2 706.6 ± 22.8 681.7 ± 18.1 F(2,36) = 1.51, p = 0.23
Positive Interference(%) –0.5 ± 1.3 1.0 ± 1.9 5.3 ± 1.7b F(2,36) = 5.09, p = 0.01
Negative Interference(%) 3.7 ± 2.0 2.7 ± 2.0 4.0 ± 2.0 F(2,36) = 0.15, p = 0.86
Left/Right task
Congruent (ms) 659.1 ± 11.6 665.7 ± 16.2 660.0 ± 16.8 F(2,38) = 0.02, p = 0.98
Incongruent (ms) 682.9 ± 11.7 678.3 ± 18.6 679.9 ± 19.1
Congruent (variable) 668.4 ± 12.8 664.3 ± 15.3 669.5 ± 17.3 F(2,38) = 0.37, p = 0.69
Incongruent(variable) 683.0 ± 12.1 689.0 ± 11.3 700.7 ± 15.6
Word Fluency
No. correct 0–30 s 7.5 ± 0.6 8.0 ± 0.5 9.0 ± 0.6b F(2,38) = 4.29, p = 0.02
No. correct 0–60 s 12.2 ± 1.0 13.0 ± 1.1 12.2 ± 0.8 F(2,38) = 0.63, p = 0.53
Tower of London
Percent correct
2-step 87.1 ± 2.7 85.3 ± 3.5 84.2 ± 3.7 No. correct:
3-step 86.0 ± 3.7 85.8 ± 3.7 85.3 ± 2.5 F(2,36) = 0.35, p = 0.71
4-step 79.5 ± 3.7 75.8 ± 5.1 80.5 ± 3.3
5-step 61.8 ± 4.9 63.7 ± 5.3 67.9 ± 5.9
Reaction time (ms)
2-step 5852 ± 410 6063 ± 564 5659 ± 429 Median reaction time:
3-step 7359 ± 615 6813 ± 639 7110 ± 697 F(2,36) = 0.33, p = 0.72
4-step 10310 ± 838 9456 ± 1133 9951 ± 954
5-step 15836 ± 1549 15894 ± 2130 15338 ± 1742
APRT
Percent correct, STM 80.5 ± 2.2 83.1 ± 2.6 78.4 ± 2.8 F(2,38) = 1.37, p = 0.26
Percent correct, LTM 77.3 ± 2.5 78.1 ± 2.7 73.7 ± 3.8 F(2,38) = 1.15, p = 0.33
Reaction time, STM (ms) 2159 ± 131 2068 ± 92.4 2195 ± 171 F(2,38) = 0.57, p = 0.57
Reaction time, LTM (ms) 2078 ± 107 1966 ± 103 1890 ± 110 F(2,38) = 1.67, p = 0.20
aBaseline = mean(intake, post-intervention session). bVersus baseline; c25% versus 100% acute tryptophan depletion (ATD). SCWT, Stroop Word Colour
test; APRT, Abstract Patterns Recognition task; STM, short-term memory; LTM, long-term memory.
significant interaction between time of rating and intervention
[F(2,36) = 7.32, p = 0.002] (Table 2). Contrast test between 
t(+6.5 h) and t(–1 h) in the high-dose condition was not significant
when the statistical outlier was included [F(1,19) = 2.51, p = 0.13]
There were no baseline differences, nor was there any difference in
mood between t(–1 h) and t(+24 h) in both conditions.
The MADRS change score data revealed two clearly separable
groups: seven patients had a change of at least 6 points (range 6–12
points), and the remaining 13 patients had no change (range –1, 2
points). This clear division allowed us to conduct post-hoc analy-
ses of the mood effect on cognitive performance by comparing
‘responders’ and ‘non-responders’, defining responders as those
who had at least a 6-point MADRS increase (see below).
Cognition
The mean ± SE of all cognitive measures are presented in Table 3.
Cognitive performance at intake and learning effects To inves-
tigate potential learning effects on the cognitive tasks in the patient
group, performance for the intake and post-intervention sessions
was compared by paired t-tests or non-parametric tests. Improved
performance was observed at the post-intervention session on all
outcome measures of the TOL, except for the number of correct
responses of the 2- and 4-step problems. A small learning effect
was also found for the Left/Right task, but only during the fixed
interval condition in both the congruent (677 versus 659 ms) and
incongruent trials (691 versus 674 ms). Patients became slower
during condition I of the Stroop Test (492 versus 509 ms). To
investigate whether high-dose ATD could influence cognitive per-
formance the next day, performances at intake and at the post-
intervention session of patients that received high-dose ATD in the
second session were compared with those that received high-dose
ATD in the first session by multivariate GLM, entering ‘order of
intervention’ as a between subjects variable. Patients who received
high-dose ATD in the second session were faster on Cards I and II
of the Neutral Stroop task at intake [Card I: F(1,18) = 7.27, p =
0.01; Card II: F(1,18) = 9.90, p = 0.01] and at the post-intervention
session [Card I: F(1,18) = 9.74, p = 0.01; Card II: F(1,18) = 6.47,
p = 0.01], indicating that the effects could not be due to the ATD
mixture.
The suitability of taking the mean of the intake and the post-
intervention sessions as a baseline measure was further checked by
a repeated measures analyses, with ‘session’ (intake versus post-
intervention session) as a within subjects factor and ‘order’ (high-
versus low-dose ATD first) as a between subjects factor. There
were no order–session interactions on any of the tests, indicating
that the average score of these two sessions can be used reliably as
a baseline score.
Effects of ATD on cognitive performance
Neutral Stroop task. Compared to baseline, ATD was associated
with decreased interference levels in a dose-dependent manner.
High-dose ATD significantly decreased interference levels com-
pared to baseline [F(1,18) = 13.41, p = 0.002] and low-dose 
ATD [(F(1,18) = 13.58, p = 0.002]. Low-dose ATD also decreased
interference levels, but the difference with baseline levels was a
statistically significant trend [(F(1,18) = 3.50, p = 0.08]. An addi-
tional analysis including depressive response as a between subjects
factor showed that responders were no more or less affected on the
Stroop task than non-responders, neither were there any order
effects. Inclusion of the statistical outlier revealed decreased inter-
ference levels in the low-dose condition [F(1,19) = 4.88, p = 0.04]
and in the high-dose condition [F(1,19) = 10.68, p = 0.004] rela-
tive to baseline, with no difference between low-and high-dose
[F(1,19) = 1.68, p = 0.21].
Emotional Stroop Task. High- but not low-dose ATD significantly
increased interference levels for positive words [F(1,18) = 15.84, 
p = 0.001], which was independent of depressive response. ATD
had no effect on interference levels for negative words. Post-hoc
inclusion of the between-subjects factor ‘responder versus non-
responder’ revealed a main effect of that variable [F(1,17) = 8.91,
p < 0.01] with higher interference levels at baseline for the respon-
ders compared to the non-responders (3.7 ± 2.0% versus –0.2 ±
1.8%), but the presence of mood was not related to the extent of
cognitive change following ATD. There were no order effects.
Other cognitive outcome measures. There were no main effects of
ATD or interaction effects with depressive response on the Left/
Right task or TOL. However, an additional analysis using gender
as a between subjects factor showed that, relative to low-dose
ATD, high-dose ATD improved performance in females but tended
to impair performance in males [F(2,34) = 7.11, p = 0.003].
Changes relative to baseline were not significant.
On the Word Fluency, ATD had no effect on the number of
words produced within 1 min. However, a more detailed analysis
showed that, within the first 30 s, high-dose ATD significantly
increased word production compared to the baseline and low-dose
ATD. There were no effects of depressive response or ATD order.
ATD had no effect on any of the outcome measures of the APRT.
Influence of minor mood changes on cognition. To investigate the
influence of minor mood changes on ATD-induced cognitive per-
formance, the GLM Repeated measures analyses on all cognitive
outcome measures were rerun entering the symptom change during
high-dose ATD session as a covariate, rather than using a categoric
division of responders and non-responders. Overall, the results
were very similar: when the responder × intervention interaction
was significant (as described above), the significant results disap-
peared after ∆MADRS was entered as a covariate; when there was
no responder × intervention interaction, entering the covariate did
not change the results.
Biochemical correlates. Changes in mood or cognitive perform-
ance during the high-dose ATD session did not correlate signifi-
cantly with percentage change of tryptophan, 5-HIAA, tyrosine or
HVA. A trend was found for percentage change of 5-HIAA levels
and changes of neutral Stroop interference (r = 0.58, p = 0.08).
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Discussion
The present study was successful in creating two ATD dosages,
lowering plasma Trp levels by 40–50% (25 g ATD; low-dose) and
by 80–90% (100 g ATD; high-dose), as intended.
As expected, high-dose ATD produced a transient return
of depressive symptoms in some participants, but not in all
(Delgado et al., 1999; Spillmann et al., 2001). Low-dose ATD did
not affect symptoms, despite a 46.8% reduction of Trp levels. The
percentage of relapse after high-dose ATD (seven out of 20) is 
relatively low compared to Delgado et al. (1990) but similar to that
reported in other studies in SSRI-treated remitted depressed
patients (Bremner et al., 1997; O’Reardon et al., 2004). Patients in
the study by Delgado et al. (1990) were clinically stable for
approximately 4 weeks, whereas patients in the study by Bremner
et al. (1997) and O’Reardon et al. (2004), as well as in the present
study, had been in remission for approximately 6 months. As noted
previously, differences in relapse rate may be related to the timing
of the ATD procedure (Booij et al., 2002).
As hypothesized, cognitive changes occurred in patients with
and without a depressive response, but the direction of change
(improvement versus impairment) was dependent of the valence of
stimuli used.
As in healthy volunteers, ATD improved focused attention for
neutral stimuli (Park et al., 1994; Schmitt et al., 2000) and the
changes in the present study were dose-dependent. Similarly, 
performance on working memory tasks (indicated by the TOL and
fluency task) also improved slightly following ATD. Improved
attentional performance following ATD may be due to the removal
of 5-HT inhibiting actions on the DA system in the prefrontal 
cortex (Schmitt et al., 2000). High-dose ATD markedly increased
tyrosine and the tyrosine/LNAA ratio, which are also involved in
mood and cognition (Booij et al., 2003). This finding was unex-
pected because ATD effects on tyrosine levels have rarely been
reported. However, a few other studies have reported rises in tyro-
sine levels (Carpenter et al., 1998; Klaassen et al., 1999). In
healthy samples, tyrosine administration improved Stroop per-
formance and working memory (Deijen et al., 1994), whereas
acute phenylalanine tyrosine depletion (APTD) selectively
impaired working memory performance (Harrison et al., 2004).
However, low-dose ATD already tended to improve Stroop inter-
ference whereas catecholamine precursors remained largely unaf-
fected. Furthermore, we found no relationship between changes in
HVA or tyrosine and cognitive performance. Because tyrosine is
also the precursor of noradrenaline, it is possible that improved
attentional performance is partly related to enhanced noradrenaline
function. It is recommended that the effects of ATD on levels of 
3-methoxy-4-hydroxyphenylglycol (MHPG) are measured, in
addition to studying APTD and ATD in the same patients.
By contrast to the effects of ATD on neutral material, high-dose
ATD increased interference for positive words. Patients became
somewhat faster in the neutral and negative word condition, but
needed more time to process positive information. Impaired emo-
tional processing was also observed in those individuals who
showed no depressive response, which is in agreement with the
results of an ATD study in healthy volunteers by Murphy et al.
(2002), who found slower responses to happy but not sad words.
Another study found that a single SSRI administration in healthy
volunteers facilitated the recognition of facial expressions of hap-
piness and fear (Harmer et al., 2003a).
Because we found no changes in symptoms following low-dose
ATD, but some changes in cognitive functioning, these cognitive
changes may be more sensitive markers of 5-HT function than
symptoms. One possibility is that cognitive changes mediate the
relationship between 5-HT and mood However, the findings are
also consistent with the idea that cognitive and symptomatic
changes occur independently.
The differential effects on attention that were found in the pres-
ent study (improvement in the processing of neutral information
versus impairment in the processing of positive information) may
be brought about by different mechanisms. At least two pathways
modulate the ATD-induced effects on mood and cognition: the
orbital/ventral medial and dorsolateral regions (Bremner et al.,
1997; Smith et al., 1999). The effects of ATD in the ventral neural
system may be different in vulnerable and non-vulnerable popula-
tions. Using positron emission tomography, a recent study identi-
fied different pathways for two emotional processing systems:
‘hot’ emotional processing (schematical processing; the actual
emotional response) and ‘cold’ emotional processing (propositional
processing; the analytical, rational mode) (Schaefer et al., 2003).
The first was associated with increased activation of the ventrome-
dial and the latter with activation of the anterolateral prefrontal
cortex (Schaefer et al., 2003). The ventral system may be more
closely implicated in 5-HT vulnerability to depression than the
dorsolateral system. Imaging studies are needed to test this 
hypothesis further.
Methodological considerations
An important issue in neuropsychopharmacological studies 
concerns choosing the optimal design. In the present study, we
compared the effects of two interventions with the mean perform-
ance during the first and fourth administration of the neuropsycho-
logical tests. This is a variant of the conventional pretest–post-test
control group design (Neale and Liebert, 1986) but, in this case, the
group variable refers only to treatment order. Unlike studies that
did not measure of baseline performance during the intervention
sessions (Park et al., 1994; Gallagher et al., 2003), learning effects
were minimal or absent. A disadvantage of the present design is
that expectancy effects during the ‘baseline’ sessions may be dif-
ferent from the effects during the depletion sessions. However, 
differences in cognitive performance between the intake session
and the post-intervention session were minimal and, if any, these
were observed on different tasks and/or in the opposite direction to
those observed at the time that Trp levels were minimized. More-
over, there were no differences between those who received low- or
high-dose ATD first. Furthermore, depletion improved perform-
ance on neutral tasks. If the test procedure influences cognitive
performance negatively (because of expectancy, fatigue, etc.),
baseline cognitive performance would have been overestimated,
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resulting in smaller differences with the depletion sessions. In
other words, the observed effects might have been bigger if a
placebo condition had been concluded. Furthermore, a true placebo
condition does not exist. Most ATD studies have used a control
mixture containing 2.3–5.0 g Trp. This procedure causes a huge
rise of Trp levels, varying from 10% to 500% (Weltzin et al., 1994;
Klaassen et al., 1999). However, moderate increments (+45%) of
Trp or Trp/LNAA ratio have been shown to affect cognitive 
performance and symptoms (Markus et al., 1998; Schruers et al.,
2000; Markus et al., 2002). Studies making a direct comparison
between cognitive performance and symptoms after a Trp-free and
Trp-containing mixture may overestimate the difference in effect.
Regarding the depressive response, the commonly used placebo
procedures have only very rarely resulted in small symptom
increases (Van der Does, 2001a), making it unlikely that the 
present study produced false positive results.
A limitation is that we did not include a control group that
received ATD, which did not allow us to investigate the interaction
between a history of depression and ATD. Thus, we do not know
whether the effects we are looking at are due to ATD itself at dif-
ferent doses, or some interaction between ATD, diagnosis and
treatment. On the other hand, most neuropsychological tasks used
in the present study have also been used in ATD studies in healthy
samples (Schmitt et al., 2000; Rubinsztein et al., 2001; Sobczak 
et al., 2002), allowing us to make indirect comparisons.
It could be argued that allowing caffeine consumption during
the ATD sessions until 1 h before the cognitive tasks comprises a
confounding factor because caffeine consumption could influence
mood, cognition and catecholamine turnover (Nehlig, 1999; Smith,
2002). On the other hand, caffeine withdrawal probably also influ-
ences behaviour during the depletion sessions because withdrawal
symptoms such as negative mood, anxiety and cognitive perform-
ance generally begin within 12–24 h, and are highest at 20–48 h
after cessation (Nehlig, 1999), even in individuals with relatively
low or moderate habitual caffeine consumption (Silverman et al.,
1992; Nehlig, 1999; Smith, 2002). In the present study, cognitive
performance during two active sessions was compared with the
mean of two baseline, no depletion sessions, sessions in which it
was not possible to keep rigid control on caffeine consumption for
some hours before administration of the cognitive tasks. In addi-
tion, differences on mood, cognition and biochemical measures
between the high- and low-dose ATD sessions were significant
despite similar caffeine restrictions. Furthermore, if caffeine con-
sumption affect symptoms, it probably occurs after excessive con-
sumption and with the largest effect on anxiety levels (Smith,
2002), which remained unaffected. Hence, it is not very likely that
the present effects are confounded by caffeine consumption.
To summarize, the present study has demonstrated that strong
reductions induce cognitive changes in patients with and without a
depressive response to ATD. Moderate reductions of Trp levels
already induce slight cognitive changes, but not a depressive
‘relapse’. The comparison of the effects of high-dose and low-dose
ATD is useful for other studies aiming to investigate relationships
among 5-HT, mood and cognition.
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